nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP1A1—breast cancer	0.201	0.573	CbGaD
Dexmedetomidine—CYP2D6—breast cancer	0.149	0.427	CbGaD
Dexmedetomidine—CYP1A1—Toremifene—breast cancer	0.0875	0.258	CbGbCtD
Dexmedetomidine—CYP1A2—Anastrozole—breast cancer	0.0428	0.126	CbGbCtD
Dexmedetomidine—CYP1A2—Toremifene—breast cancer	0.0391	0.115	CbGbCtD
Dexmedetomidine—CYP1A1—Tamoxifen—breast cancer	0.032	0.0942	CbGbCtD
Dexmedetomidine—CYP2D6—Idarubicin—breast cancer	0.0267	0.0786	CbGbCtD
Dexmedetomidine—CYP2E1—Tamoxifen—breast cancer	0.0247	0.0728	CbGbCtD
Dexmedetomidine—CYP2E1—Mitoxantrone—breast cancer	0.0241	0.071	CbGbCtD
Dexmedetomidine—CYP1A2—Tamoxifen—breast cancer	0.0143	0.0421	CbGbCtD
Dexmedetomidine—CYP2D6—Vinorelbine—breast cancer	0.013	0.0384	CbGbCtD
Dexmedetomidine—CYP2D6—Tamoxifen—breast cancer	0.0118	0.0347	CbGbCtD
Dexmedetomidine—CYP1A2—Fluorouracil—breast cancer	0.0105	0.031	CbGbCtD
Dexmedetomidine—CYP2D6—Vinblastine—breast cancer	0.00804	0.0237	CbGbCtD
Dexmedetomidine—CYP2D6—Doxorubicin—breast cancer	0.00494	0.0145	CbGbCtD
Dexmedetomidine—ADRA1D—epithelium—breast cancer	0.000349	0.0581	CbGeAlD
Dexmedetomidine—ADRA2C—nipple—breast cancer	0.000284	0.0472	CbGeAlD
Dexmedetomidine—ADRA1D—female reproductive system—breast cancer	0.000259	0.0431	CbGeAlD
Dexmedetomidine—CYP1A2—nipple—breast cancer	0.000246	0.041	CbGeAlD
Dexmedetomidine—CYP1A1—nipple—breast cancer	0.000243	0.0404	CbGeAlD
Dexmedetomidine—ADRA2A—nipple—breast cancer	0.000226	0.0377	CbGeAlD
Dexmedetomidine—ADRA1D—endocrine gland—breast cancer	0.000219	0.0365	CbGeAlD
Dexmedetomidine—ADRA2C—endometrium—breast cancer	0.000171	0.0285	CbGeAlD
Dexmedetomidine—CYP1A1—epithelium—breast cancer	0.000164	0.0272	CbGeAlD
Dexmedetomidine—SLC6A2—female reproductive system—breast cancer	0.00016	0.0267	CbGeAlD
Dexmedetomidine—ADRA2C—uterus—breast cancer	0.000158	0.0263	CbGeAlD
Dexmedetomidine—SLC6A2—adrenal gland—breast cancer	0.000156	0.026	CbGeAlD
Dexmedetomidine—CYP1A1—skin of body—breast cancer	0.000156	0.0259	CbGeAlD
Dexmedetomidine—ADRA2C—pituitary gland—breast cancer	0.000155	0.0258	CbGeAlD
Dexmedetomidine—ADRA2C—adipose tissue—breast cancer	0.000154	0.0257	CbGeAlD
Dexmedetomidine—ADRA2C—adrenal gland—breast cancer	0.000138	0.023	CbGeAlD
Dexmedetomidine—ADRA2A—endometrium—breast cancer	0.000137	0.0227	CbGeAlD
Dexmedetomidine—SLC6A2—endocrine gland—breast cancer	0.000136	0.0226	CbGeAlD
Dexmedetomidine—CYP1A1—uterus—breast cancer	0.000135	0.0225	CbGeAlD
Dexmedetomidine—CYP1A1—adipose tissue—breast cancer	0.000132	0.022	CbGeAlD
Dexmedetomidine—ADRA2C—female gonad—breast cancer	0.000129	0.0215	CbGeAlD
Dexmedetomidine—ADRA2A—uterus—breast cancer	0.000126	0.021	CbGeAlD
Dexmedetomidine—ADRA2A—pituitary gland—breast cancer	0.000124	0.0206	CbGeAlD
Dexmedetomidine—ADRA2A—adipose tissue—breast cancer	0.000123	0.0205	CbGeAlD
Dexmedetomidine—CYP1A1—female reproductive system—breast cancer	0.000121	0.0202	CbGeAlD
Dexmedetomidine—ADRA2A—female reproductive system—breast cancer	0.000113	0.0188	CbGeAlD
Dexmedetomidine—CYP2E1—female reproductive system—breast cancer	0.000111	0.0184	CbGeAlD
Dexmedetomidine—CYP1A1—female gonad—breast cancer	0.000111	0.0184	CbGeAlD
Dexmedetomidine—ADRA2A—adrenal gland—breast cancer	0.00011	0.0184	CbGeAlD
Dexmedetomidine—CYP2E1—adrenal gland—breast cancer	0.000108	0.018	CbGeAlD
Dexmedetomidine—CYP1A2—endocrine gland—breast cancer	0.000104	0.0173	CbGeAlD
Dexmedetomidine—ADRA2A—female gonad—breast cancer	0.000103	0.0171	CbGeAlD
Dexmedetomidine—CYP1A1—endocrine gland—breast cancer	0.000103	0.0171	CbGeAlD
Dexmedetomidine—ADRA2A—endocrine gland—breast cancer	9.58e-05	0.0159	CbGeAlD
Dexmedetomidine—CYP2E1—endocrine gland—breast cancer	9.37e-05	0.0156	CbGeAlD
Dexmedetomidine—SLC6A2—lymph node—breast cancer	9.37e-05	0.0156	CbGeAlD
Dexmedetomidine—CYP2D6—female reproductive system—breast cancer	8.77e-05	0.0146	CbGeAlD
Dexmedetomidine—ADRA2C—lymph node—breast cancer	8.3e-05	0.0138	CbGeAlD
Dexmedetomidine—CYP2D6—female gonad—breast cancer	7.98e-05	0.0133	CbGeAlD
Dexmedetomidine—Feeling abnormal—Mitoxantrone—breast cancer	7.6e-05	0.000373	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Irinotecan—breast cancer	7.6e-05	0.000373	CcSEcCtD
Dexmedetomidine—Confusional state—Paclitaxel—breast cancer	7.58e-05	0.000372	CcSEcCtD
Dexmedetomidine—Malnutrition—Capecitabine—breast cancer	7.56e-05	0.000371	CcSEcCtD
Dexmedetomidine—Pain—Fluorouracil—breast cancer	7.55e-05	0.000371	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Irinotecan—breast cancer	7.54e-05	0.00037	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Mitoxantrone—breast cancer	7.54e-05	0.00037	CcSEcCtD
Dexmedetomidine—Infection—Paclitaxel—breast cancer	7.47e-05	0.000367	CcSEcCtD
Dexmedetomidine—CYP2D6—endocrine gland—breast cancer	7.42e-05	0.0123	CbGeAlD
Dexmedetomidine—Nausea—Goserelin—breast cancer	7.42e-05	0.000364	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Gemcitabine—breast cancer	7.4e-05	0.000363	CcSEcCtD
Dexmedetomidine—Dizziness—Vinorelbine—breast cancer	7.4e-05	0.000363	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Doxorubicin—breast cancer	7.37e-05	0.000361	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Paclitaxel—breast cancer	7.37e-05	0.000361	CcSEcCtD
Dexmedetomidine—Tachycardia—Paclitaxel—breast cancer	7.34e-05	0.00036	CcSEcCtD
Dexmedetomidine—Diarrhoea—Thiotepa—breast cancer	7.31e-05	0.000358	CcSEcCtD
Dexmedetomidine—Abdominal pain—Irinotecan—breast cancer	7.29e-05	0.000358	CcSEcCtD
Dexmedetomidine—Abdominal pain—Mitoxantrone—breast cancer	7.29e-05	0.000358	CcSEcCtD
Dexmedetomidine—Body temperature increased—Mitoxantrone—breast cancer	7.29e-05	0.000358	CcSEcCtD
Dexmedetomidine—Body temperature increased—Irinotecan—breast cancer	7.29e-05	0.000358	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Doxorubicin—breast cancer	7.29e-05	0.000358	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Fluorouracil—breast cancer	7.28e-05	0.000357	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Paclitaxel—breast cancer	7.27e-05	0.000357	CcSEcCtD
Dexmedetomidine—Pneumonia—Methotrexate—breast cancer	7.25e-05	0.000355	CcSEcCtD
Dexmedetomidine—Anaemia—Docetaxel—breast cancer	7.22e-05	0.000354	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Doxorubicin—breast cancer	7.14e-05	0.00035	CcSEcCtD
Dexmedetomidine—Vomiting—Vinorelbine—breast cancer	7.11e-05	0.000349	CcSEcCtD
Dexmedetomidine—CYP1A1—lymph node—breast cancer	7.11e-05	0.0118	CbGeAlD
Dexmedetomidine—Body temperature increased—Gemcitabine—breast cancer	7.1e-05	0.000348	CcSEcCtD
Dexmedetomidine—Dizziness—Thiotepa—breast cancer	7.06e-05	0.000346	CcSEcCtD
Dexmedetomidine—Rash—Vinorelbine—breast cancer	7.05e-05	0.000346	CcSEcCtD
Dexmedetomidine—Dermatitis—Vinorelbine—breast cancer	7.05e-05	0.000346	CcSEcCtD
Dexmedetomidine—Abdominal distension—Doxorubicin—breast cancer	7.04e-05	0.000346	CcSEcCtD
Dexmedetomidine—Hypotension—Paclitaxel—breast cancer	7.03e-05	0.000345	CcSEcCtD
Dexmedetomidine—Headache—Vinorelbine—breast cancer	7.01e-05	0.000344	CcSEcCtD
Dexmedetomidine—Anaemia—Capecitabine—breast cancer	6.99e-05	0.000343	CcSEcCtD
Dexmedetomidine—Body temperature increased—Fluorouracil—breast cancer	6.98e-05	0.000343	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Epirubicin—breast cancer	6.82e-05	0.000335	CcSEcCtD
Dexmedetomidine—Vomiting—Thiotepa—breast cancer	6.79e-05	0.000333	CcSEcCtD
Dexmedetomidine—Pneumonia—Epirubicin—breast cancer	6.78e-05	0.000333	CcSEcCtD
Dexmedetomidine—Convulsion—Docetaxel—breast cancer	6.77e-05	0.000332	CcSEcCtD
Dexmedetomidine—Hypertension—Docetaxel—breast cancer	6.74e-05	0.000331	CcSEcCtD
Dexmedetomidine—Rash—Thiotepa—breast cancer	6.73e-05	0.00033	CcSEcCtD
Dexmedetomidine—Dermatitis—Thiotepa—breast cancer	6.73e-05	0.00033	CcSEcCtD
Dexmedetomidine—Dyspnoea—Paclitaxel—breast cancer	6.71e-05	0.000329	CcSEcCtD
Dexmedetomidine—Headache—Thiotepa—breast cancer	6.69e-05	0.000328	CcSEcCtD
Dexmedetomidine—Somnolence—Paclitaxel—breast cancer	6.69e-05	0.000328	CcSEcCtD
Dexmedetomidine—Nausea—Vinorelbine—breast cancer	6.64e-05	0.000326	CcSEcCtD
Dexmedetomidine—ADRA2A—lymph node—breast cancer	6.62e-05	0.011	CbGeAlD
Dexmedetomidine—Neuropathy peripheral—Epirubicin—breast cancer	6.61e-05	0.000324	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Epirubicin—breast cancer	6.55e-05	0.000321	CcSEcCtD
Dexmedetomidine—Hypertension—Capecitabine—breast cancer	6.53e-05	0.00032	CcSEcCtD
Dexmedetomidine—Dry mouth—Docetaxel—breast cancer	6.5e-05	0.000319	CcSEcCtD
Dexmedetomidine—Haemoglobin—Methotrexate—breast cancer	6.5e-05	0.000319	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Paclitaxel—breast cancer	6.49e-05	0.000319	CcSEcCtD
Dexmedetomidine—Haemorrhage—Methotrexate—breast cancer	6.47e-05	0.000317	CcSEcCtD
Dexmedetomidine—Constipation—Paclitaxel—breast cancer	6.43e-05	0.000315	CcSEcCtD
Dexmedetomidine—Pain—Paclitaxel—breast cancer	6.43e-05	0.000315	CcSEcCtD
Dexmedetomidine—Confusional state—Docetaxel—breast cancer	6.43e-05	0.000315	CcSEcCtD
Dexmedetomidine—Anxiety—Capecitabine—breast cancer	6.42e-05	0.000315	CcSEcCtD
Dexmedetomidine—Nausea—Thiotepa—breast cancer	6.34e-05	0.000311	CcSEcCtD
Dexmedetomidine—Infection—Docetaxel—breast cancer	6.33e-05	0.000311	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Doxorubicin—breast cancer	6.31e-05	0.00031	CcSEcCtD
Dexmedetomidine—Diarrhoea—Irinotecan—breast cancer	6.31e-05	0.00031	CcSEcCtD
Dexmedetomidine—Diarrhoea—Mitoxantrone—breast cancer	6.31e-05	0.00031	CcSEcCtD
Dexmedetomidine—Dry mouth—Capecitabine—breast cancer	6.3e-05	0.000309	CcSEcCtD
Dexmedetomidine—Pneumonia—Doxorubicin—breast cancer	6.28e-05	0.000308	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Docetaxel—breast cancer	6.24e-05	0.000306	CcSEcCtD
Dexmedetomidine—Visual impairment—Methotrexate—breast cancer	6.23e-05	0.000306	CcSEcCtD
Dexmedetomidine—Confusional state—Capecitabine—breast cancer	6.22e-05	0.000305	CcSEcCtD
Dexmedetomidine—Tachycardia—Docetaxel—breast cancer	6.22e-05	0.000305	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Paclitaxel—breast cancer	6.2e-05	0.000304	CcSEcCtD
Dexmedetomidine—Bradycardia—Epirubicin—breast cancer	6.16e-05	0.000302	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Paclitaxel—breast cancer	6.15e-05	0.000302	CcSEcCtD
Dexmedetomidine—Diarrhoea—Gemcitabine—breast cancer	6.15e-05	0.000302	CcSEcCtD
Dexmedetomidine—Infection—Capecitabine—breast cancer	6.13e-05	0.000301	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Doxorubicin—breast cancer	6.12e-05	0.0003	CcSEcCtD
Dexmedetomidine—Dizziness—Irinotecan—breast cancer	6.1e-05	0.000299	CcSEcCtD
Dexmedetomidine—Haemoglobin—Epirubicin—breast cancer	6.08e-05	0.000298	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Doxorubicin—breast cancer	6.06e-05	0.000297	CcSEcCtD
Dexmedetomidine—Haemorrhage—Epirubicin—breast cancer	6.05e-05	0.000297	CcSEcCtD
Dexmedetomidine—Diarrhoea—Fluorouracil—breast cancer	6.04e-05	0.000296	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Capecitabine—breast cancer	6.04e-05	0.000296	CcSEcCtD
Dexmedetomidine—Tachycardia—Capecitabine—breast cancer	6.02e-05	0.000295	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Methotrexate—breast cancer	6e-05	0.000294	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Capecitabine—breast cancer	5.97e-05	0.000293	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Epirubicin—breast cancer	5.96e-05	0.000292	CcSEcCtD
Dexmedetomidine—Hypotension—Docetaxel—breast cancer	5.96e-05	0.000292	CcSEcCtD
Dexmedetomidine—Abdominal pain—Paclitaxel—breast cancer	5.95e-05	0.000292	CcSEcCtD
Dexmedetomidine—Body temperature increased—Paclitaxel—breast cancer	5.95e-05	0.000292	CcSEcCtD
Dexmedetomidine—Angiopathy—Methotrexate—breast cancer	5.87e-05	0.000288	CcSEcCtD
Dexmedetomidine—Vomiting—Mitoxantrone—breast cancer	5.86e-05	0.000288	CcSEcCtD
Dexmedetomidine—Vomiting—Irinotecan—breast cancer	5.86e-05	0.000288	CcSEcCtD
Dexmedetomidine—Dizziness—Fluorouracil—breast cancer	5.84e-05	0.000287	CcSEcCtD
Dexmedetomidine—Visual impairment—Epirubicin—breast cancer	5.83e-05	0.000286	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Methotrexate—breast cancer	5.83e-05	0.000286	CcSEcCtD
Dexmedetomidine—Rash—Irinotecan—breast cancer	5.82e-05	0.000285	CcSEcCtD
Dexmedetomidine—Rash—Mitoxantrone—breast cancer	5.82e-05	0.000285	CcSEcCtD
Dexmedetomidine—Dermatitis—Mitoxantrone—breast cancer	5.81e-05	0.000285	CcSEcCtD
Dexmedetomidine—Dermatitis—Irinotecan—breast cancer	5.81e-05	0.000285	CcSEcCtD
Dexmedetomidine—Chills—Methotrexate—breast cancer	5.8e-05	0.000285	CcSEcCtD
Dexmedetomidine—Headache—Irinotecan—breast cancer	5.78e-05	0.000283	CcSEcCtD
Dexmedetomidine—Headache—Mitoxantrone—breast cancer	5.78e-05	0.000283	CcSEcCtD
Dexmedetomidine—Hypotension—Capecitabine—breast cancer	5.77e-05	0.000283	CcSEcCtD
Dexmedetomidine—Vomiting—Gemcitabine—breast cancer	5.71e-05	0.00028	CcSEcCtD
Dexmedetomidine—Bradycardia—Doxorubicin—breast cancer	5.7e-05	0.00028	CcSEcCtD
Dexmedetomidine—Dyspnoea—Docetaxel—breast cancer	5.68e-05	0.000279	CcSEcCtD
Dexmedetomidine—Somnolence—Docetaxel—breast cancer	5.67e-05	0.000278	CcSEcCtD
Dexmedetomidine—Mental disorder—Methotrexate—breast cancer	5.67e-05	0.000278	CcSEcCtD
Dexmedetomidine—Rash—Gemcitabine—breast cancer	5.67e-05	0.000278	CcSEcCtD
Dexmedetomidine—Dermatitis—Gemcitabine—breast cancer	5.66e-05	0.000278	CcSEcCtD
Dexmedetomidine—Malnutrition—Methotrexate—breast cancer	5.63e-05	0.000276	CcSEcCtD
Dexmedetomidine—Haemoglobin—Doxorubicin—breast cancer	5.63e-05	0.000276	CcSEcCtD
Dexmedetomidine—Headache—Gemcitabine—breast cancer	5.63e-05	0.000276	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Epirubicin—breast cancer	5.62e-05	0.000276	CcSEcCtD
Dexmedetomidine—Vomiting—Fluorouracil—breast cancer	5.62e-05	0.000275	CcSEcCtD
Dexmedetomidine—Haemorrhage—Doxorubicin—breast cancer	5.6e-05	0.000275	CcSEcCtD
Dexmedetomidine—Rash—Fluorouracil—breast cancer	5.57e-05	0.000273	CcSEcCtD
Dexmedetomidine—Dermatitis—Fluorouracil—breast cancer	5.56e-05	0.000273	CcSEcCtD
Dexmedetomidine—Headache—Fluorouracil—breast cancer	5.53e-05	0.000271	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Doxorubicin—breast cancer	5.52e-05	0.000271	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Docetaxel—breast cancer	5.5e-05	0.00027	CcSEcCtD
Dexmedetomidine—Dyspnoea—Capecitabine—breast cancer	5.5e-05	0.00027	CcSEcCtD
Dexmedetomidine—Angiopathy—Epirubicin—breast cancer	5.49e-05	0.000269	CcSEcCtD
Dexmedetomidine—Nausea—Irinotecan—breast cancer	5.48e-05	0.000269	CcSEcCtD
Dexmedetomidine—Nausea—Mitoxantrone—breast cancer	5.48e-05	0.000269	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Epirubicin—breast cancer	5.46e-05	0.000268	CcSEcCtD
Dexmedetomidine—Constipation—Docetaxel—breast cancer	5.45e-05	0.000267	CcSEcCtD
Dexmedetomidine—Pain—Docetaxel—breast cancer	5.45e-05	0.000267	CcSEcCtD
Dexmedetomidine—Chills—Epirubicin—breast cancer	5.43e-05	0.000266	CcSEcCtD
Dexmedetomidine—Arrhythmia—Epirubicin—breast cancer	5.41e-05	0.000265	CcSEcCtD
Dexmedetomidine—Visual impairment—Doxorubicin—breast cancer	5.4e-05	0.000265	CcSEcCtD
Dexmedetomidine—Nausea—Gemcitabine—breast cancer	5.34e-05	0.000262	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Capecitabine—breast cancer	5.33e-05	0.000261	CcSEcCtD
Dexmedetomidine—Mental disorder—Epirubicin—breast cancer	5.3e-05	0.00026	CcSEcCtD
Dexmedetomidine—Pain—Capecitabine—breast cancer	5.28e-05	0.000259	CcSEcCtD
Dexmedetomidine—Constipation—Capecitabine—breast cancer	5.28e-05	0.000259	CcSEcCtD
Dexmedetomidine—Malnutrition—Epirubicin—breast cancer	5.27e-05	0.000258	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Docetaxel—breast cancer	5.25e-05	0.000258	CcSEcCtD
Dexmedetomidine—Nausea—Fluorouracil—breast cancer	5.25e-05	0.000257	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Docetaxel—breast cancer	5.21e-05	0.000256	CcSEcCtD
Dexmedetomidine—Anaemia—Methotrexate—breast cancer	5.2e-05	0.000255	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Doxorubicin—breast cancer	5.2e-05	0.000255	CcSEcCtD
Dexmedetomidine—Diarrhoea—Paclitaxel—breast cancer	5.15e-05	0.000252	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Capecitabine—breast cancer	5.09e-05	0.000249	CcSEcCtD
Dexmedetomidine—Angiopathy—Doxorubicin—breast cancer	5.08e-05	0.000249	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Capecitabine—breast cancer	5.05e-05	0.000248	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Doxorubicin—breast cancer	5.05e-05	0.000248	CcSEcCtD
Dexmedetomidine—Abdominal pain—Docetaxel—breast cancer	5.04e-05	0.000247	CcSEcCtD
Dexmedetomidine—Body temperature increased—Docetaxel—breast cancer	5.04e-05	0.000247	CcSEcCtD
Dexmedetomidine—Chills—Doxorubicin—breast cancer	5.03e-05	0.000246	CcSEcCtD
Dexmedetomidine—Arrhythmia—Doxorubicin—breast cancer	5e-05	0.000245	CcSEcCtD
Dexmedetomidine—Dizziness—Paclitaxel—breast cancer	4.97e-05	0.000244	CcSEcCtD
Dexmedetomidine—Mental disorder—Doxorubicin—breast cancer	4.91e-05	0.000241	CcSEcCtD
Dexmedetomidine—Body temperature increased—Capecitabine—breast cancer	4.88e-05	0.000239	CcSEcCtD
Dexmedetomidine—Abdominal pain—Capecitabine—breast cancer	4.88e-05	0.000239	CcSEcCtD
Dexmedetomidine—Convulsion—Methotrexate—breast cancer	4.88e-05	0.000239	CcSEcCtD
Dexmedetomidine—Malnutrition—Doxorubicin—breast cancer	4.88e-05	0.000239	CcSEcCtD
Dexmedetomidine—Anaemia—Epirubicin—breast cancer	4.87e-05	0.000239	CcSEcCtD
Dexmedetomidine—Agitation—Epirubicin—breast cancer	4.84e-05	0.000238	CcSEcCtD
Dexmedetomidine—Vomiting—Paclitaxel—breast cancer	4.78e-05	0.000235	CcSEcCtD
Dexmedetomidine—Rash—Paclitaxel—breast cancer	4.74e-05	0.000233	CcSEcCtD
Dexmedetomidine—Dermatitis—Paclitaxel—breast cancer	4.74e-05	0.000232	CcSEcCtD
Dexmedetomidine—Headache—Paclitaxel—breast cancer	4.71e-05	0.000231	CcSEcCtD
Dexmedetomidine—Confusional state—Methotrexate—breast cancer	4.63e-05	0.000227	CcSEcCtD
Dexmedetomidine—Convulsion—Epirubicin—breast cancer	4.57e-05	0.000224	CcSEcCtD
Dexmedetomidine—Infection—Methotrexate—breast cancer	4.57e-05	0.000224	CcSEcCtD
Dexmedetomidine—Hypertension—Epirubicin—breast cancer	4.55e-05	0.000223	CcSEcCtD
Dexmedetomidine—Anaemia—Doxorubicin—breast cancer	4.51e-05	0.000221	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Methotrexate—breast cancer	4.5e-05	0.000221	CcSEcCtD
Dexmedetomidine—Agitation—Doxorubicin—breast cancer	4.48e-05	0.00022	CcSEcCtD
Dexmedetomidine—Anxiety—Epirubicin—breast cancer	4.47e-05	0.000219	CcSEcCtD
Dexmedetomidine—Nausea—Paclitaxel—breast cancer	4.47e-05	0.000219	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Methotrexate—breast cancer	4.44e-05	0.000218	CcSEcCtD
Dexmedetomidine—Dry mouth—Epirubicin—breast cancer	4.39e-05	0.000215	CcSEcCtD
Dexmedetomidine—Diarrhoea—Docetaxel—breast cancer	4.36e-05	0.000214	CcSEcCtD
Dexmedetomidine—Confusional state—Epirubicin—breast cancer	4.34e-05	0.000213	CcSEcCtD
Dexmedetomidine—Hypotension—Methotrexate—breast cancer	4.29e-05	0.000211	CcSEcCtD
Dexmedetomidine—Infection—Epirubicin—breast cancer	4.27e-05	0.00021	CcSEcCtD
Dexmedetomidine—Convulsion—Doxorubicin—breast cancer	4.22e-05	0.000207	CcSEcCtD
Dexmedetomidine—Diarrhoea—Capecitabine—breast cancer	4.22e-05	0.000207	CcSEcCtD
Dexmedetomidine—Dizziness—Docetaxel—breast cancer	4.22e-05	0.000207	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Epirubicin—breast cancer	4.21e-05	0.000207	CcSEcCtD
Dexmedetomidine—Hypertension—Doxorubicin—breast cancer	4.21e-05	0.000206	CcSEcCtD
Dexmedetomidine—Tachycardia—Epirubicin—breast cancer	4.2e-05	0.000206	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Epirubicin—breast cancer	4.16e-05	0.000204	CcSEcCtD
Dexmedetomidine—Anxiety—Doxorubicin—breast cancer	4.14e-05	0.000203	CcSEcCtD
Dexmedetomidine—Dyspnoea—Methotrexate—breast cancer	4.1e-05	0.000201	CcSEcCtD
Dexmedetomidine—Somnolence—Methotrexate—breast cancer	4.09e-05	0.0002	CcSEcCtD
Dexmedetomidine—Dizziness—Capecitabine—breast cancer	4.08e-05	0.0002	CcSEcCtD
Dexmedetomidine—Dry mouth—Doxorubicin—breast cancer	4.06e-05	0.000199	CcSEcCtD
Dexmedetomidine—Vomiting—Docetaxel—breast cancer	4.05e-05	0.000199	CcSEcCtD
Dexmedetomidine—Rash—Docetaxel—breast cancer	4.02e-05	0.000197	CcSEcCtD
Dexmedetomidine—Hypotension—Epirubicin—breast cancer	4.02e-05	0.000197	CcSEcCtD
Dexmedetomidine—Dermatitis—Docetaxel—breast cancer	4.02e-05	0.000197	CcSEcCtD
Dexmedetomidine—Confusional state—Doxorubicin—breast cancer	4.01e-05	0.000197	CcSEcCtD
Dexmedetomidine—Headache—Docetaxel—breast cancer	3.99e-05	0.000196	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Methotrexate—breast cancer	3.97e-05	0.000195	CcSEcCtD
Dexmedetomidine—Infection—Doxorubicin—breast cancer	3.95e-05	0.000194	CcSEcCtD
Dexmedetomidine—Pain—Methotrexate—breast cancer	3.93e-05	0.000193	CcSEcCtD
Dexmedetomidine—Vomiting—Capecitabine—breast cancer	3.93e-05	0.000193	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Doxorubicin—breast cancer	3.9e-05	0.000191	CcSEcCtD
Dexmedetomidine—Rash—Capecitabine—breast cancer	3.89e-05	0.000191	CcSEcCtD
Dexmedetomidine—Dermatitis—Capecitabine—breast cancer	3.89e-05	0.000191	CcSEcCtD
Dexmedetomidine—Tachycardia—Doxorubicin—breast cancer	3.88e-05	0.00019	CcSEcCtD
Dexmedetomidine—Headache—Capecitabine—breast cancer	3.87e-05	0.00019	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Doxorubicin—breast cancer	3.85e-05	0.000189	CcSEcCtD
Dexmedetomidine—Dyspnoea—Epirubicin—breast cancer	3.83e-05	0.000188	CcSEcCtD
Dexmedetomidine—Somnolence—Epirubicin—breast cancer	3.82e-05	0.000188	CcSEcCtD
Dexmedetomidine—Nausea—Docetaxel—breast cancer	3.79e-05	0.000186	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Methotrexate—breast cancer	3.79e-05	0.000186	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Methotrexate—breast cancer	3.76e-05	0.000184	CcSEcCtD
Dexmedetomidine—Hypotension—Doxorubicin—breast cancer	3.72e-05	0.000182	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Epirubicin—breast cancer	3.71e-05	0.000182	CcSEcCtD
Dexmedetomidine—Constipation—Epirubicin—breast cancer	3.68e-05	0.00018	CcSEcCtD
Dexmedetomidine—Pain—Epirubicin—breast cancer	3.68e-05	0.00018	CcSEcCtD
Dexmedetomidine—Nausea—Capecitabine—breast cancer	3.67e-05	0.00018	CcSEcCtD
Dexmedetomidine—Abdominal pain—Methotrexate—breast cancer	3.63e-05	0.000178	CcSEcCtD
Dexmedetomidine—Body temperature increased—Methotrexate—breast cancer	3.63e-05	0.000178	CcSEcCtD
Dexmedetomidine—Dyspnoea—Doxorubicin—breast cancer	3.55e-05	0.000174	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Epirubicin—breast cancer	3.54e-05	0.000174	CcSEcCtD
Dexmedetomidine—Somnolence—Doxorubicin—breast cancer	3.54e-05	0.000174	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Epirubicin—breast cancer	3.52e-05	0.000172	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Doxorubicin—breast cancer	3.44e-05	0.000168	CcSEcCtD
Dexmedetomidine—Constipation—Doxorubicin—breast cancer	3.4e-05	0.000167	CcSEcCtD
Dexmedetomidine—Pain—Doxorubicin—breast cancer	3.4e-05	0.000167	CcSEcCtD
Dexmedetomidine—Abdominal pain—Epirubicin—breast cancer	3.4e-05	0.000167	CcSEcCtD
Dexmedetomidine—Body temperature increased—Epirubicin—breast cancer	3.4e-05	0.000167	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Doxorubicin—breast cancer	3.28e-05	0.000161	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Doxorubicin—breast cancer	3.25e-05	0.00016	CcSEcCtD
Dexmedetomidine—Abdominal pain—Doxorubicin—breast cancer	3.15e-05	0.000154	CcSEcCtD
Dexmedetomidine—Body temperature increased—Doxorubicin—breast cancer	3.15e-05	0.000154	CcSEcCtD
Dexmedetomidine—Diarrhoea—Methotrexate—breast cancer	3.14e-05	0.000154	CcSEcCtD
Dexmedetomidine—Dizziness—Methotrexate—breast cancer	3.04e-05	0.000149	CcSEcCtD
Dexmedetomidine—Diarrhoea—Epirubicin—breast cancer	2.94e-05	0.000144	CcSEcCtD
Dexmedetomidine—Vomiting—Methotrexate—breast cancer	2.92e-05	0.000143	CcSEcCtD
Dexmedetomidine—Rash—Methotrexate—breast cancer	2.9e-05	0.000142	CcSEcCtD
Dexmedetomidine—Dermatitis—Methotrexate—breast cancer	2.89e-05	0.000142	CcSEcCtD
Dexmedetomidine—Headache—Methotrexate—breast cancer	2.88e-05	0.000141	CcSEcCtD
Dexmedetomidine—Dizziness—Epirubicin—breast cancer	2.84e-05	0.000139	CcSEcCtD
Dexmedetomidine—Vomiting—Epirubicin—breast cancer	2.73e-05	0.000134	CcSEcCtD
Dexmedetomidine—Nausea—Methotrexate—breast cancer	2.73e-05	0.000134	CcSEcCtD
Dexmedetomidine—Diarrhoea—Doxorubicin—breast cancer	2.72e-05	0.000134	CcSEcCtD
Dexmedetomidine—Rash—Epirubicin—breast cancer	2.71e-05	0.000133	CcSEcCtD
Dexmedetomidine—Dermatitis—Epirubicin—breast cancer	2.71e-05	0.000133	CcSEcCtD
Dexmedetomidine—Headache—Epirubicin—breast cancer	2.69e-05	0.000132	CcSEcCtD
Dexmedetomidine—Dizziness—Doxorubicin—breast cancer	2.63e-05	0.000129	CcSEcCtD
Dexmedetomidine—Nausea—Epirubicin—breast cancer	2.55e-05	0.000125	CcSEcCtD
Dexmedetomidine—Vomiting—Doxorubicin—breast cancer	2.53e-05	0.000124	CcSEcCtD
Dexmedetomidine—Rash—Doxorubicin—breast cancer	2.51e-05	0.000123	CcSEcCtD
Dexmedetomidine—Dermatitis—Doxorubicin—breast cancer	2.51e-05	0.000123	CcSEcCtD
Dexmedetomidine—Headache—Doxorubicin—breast cancer	2.49e-05	0.000122	CcSEcCtD
Dexmedetomidine—Nausea—Doxorubicin—breast cancer	2.36e-05	0.000116	CcSEcCtD
Dexmedetomidine—ADRA1B—Signaling by GPCR—KRAS—breast cancer	3.55e-06	3.53e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PIK3CA—breast cancer	3.55e-06	3.53e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—AKT1—breast cancer	3.54e-06	3.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MDM2—breast cancer	3.54e-06	3.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ALB—breast cancer	3.54e-06	3.51e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CG—breast cancer	3.53e-06	3.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—RAF1—breast cancer	3.52e-06	3.5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NFKBIA—breast cancer	3.52e-06	3.5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—RELA—breast cancer	3.51e-06	3.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CASP3—breast cancer	3.5e-06	3.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL2—breast cancer	3.5e-06	3.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ERBB2—breast cancer	3.49e-06	3.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOTCH1—breast cancer	3.48e-06	3.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL6—breast cancer	3.48e-06	3.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NOS3—breast cancer	3.48e-06	3.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MTOR—breast cancer	3.44e-06	3.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CB—breast cancer	3.44e-06	3.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NOS3—breast cancer	3.43e-06	3.41e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GPX1—breast cancer	3.42e-06	3.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCND1—breast cancer	3.41e-06	3.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APC—breast cancer	3.41e-06	3.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CG—breast cancer	3.41e-06	3.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KIT—breast cancer	3.41e-06	3.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—JUN—breast cancer	3.4e-06	3.38e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP1A1—breast cancer	3.39e-06	3.37e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—NOS3—breast cancer	3.38e-06	3.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CTNNB1—breast cancer	3.38e-06	3.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGF—breast cancer	3.37e-06	3.35e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ERCC2—breast cancer	3.36e-06	3.34e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	3.34e-06	3.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTEN—breast cancer	3.32e-06	3.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PIK3CA—breast cancer	3.32e-06	3.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MMP9—breast cancer	3.31e-06	3.29e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—COMT—breast cancer	3.31e-06	3.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCL8—breast cancer	3.31e-06	3.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MDM2—breast cancer	3.3e-06	3.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1A—breast cancer	3.3e-06	3.28e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTP1—breast cancer	3.3e-06	3.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PTEN—breast cancer	3.29e-06	3.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—RAF1—breast cancer	3.29e-06	3.27e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CD—breast cancer	3.29e-06	3.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—HRAS—breast cancer	3.28e-06	3.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—RELA—breast cancer	3.28e-06	3.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PIK3CA—breast cancer	3.26e-06	3.24e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—MAPK3—breast cancer	3.26e-06	3.24e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ERBB2—breast cancer	3.26e-06	3.24e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MDM2—breast cancer	3.25e-06	3.23e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—HMOX1—breast cancer	3.25e-06	3.23e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ALB—breast cancer	3.25e-06	3.23e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ITPR1—breast cancer	3.24e-06	3.22e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—RAF1—breast cancer	3.24e-06	3.22e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1B—breast cancer	3.23e-06	3.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—RELA—breast cancer	3.23e-06	3.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK8—breast cancer	3.22e-06	3.2e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MTOR—breast cancer	3.21e-06	3.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CB—breast cancer	3.21e-06	3.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—AKT1—breast cancer	3.21e-06	3.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ERBB2—breast cancer	3.2e-06	3.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—BRAF—breast cancer	3.2e-06	3.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—AKT1—breast cancer	3.19e-06	3.17e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CASP3—breast cancer	3.16e-06	3.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CB—breast cancer	3.16e-06	3.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MTOR—breast cancer	3.16e-06	3.14e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—MTHFR—breast cancer	3.16e-06	3.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL2—breast cancer	3.16e-06	3.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL6—breast cancer	3.14e-06	3.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CB—breast cancer	3.12e-06	3.1e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ABCB1—breast cancer	3.12e-06	3.1e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IGF1—breast cancer	3.12e-06	3.1e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKT2—breast cancer	3.12e-06	3.1e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—NOS3—breast cancer	3.11e-06	3.09e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—breast cancer	3.1e-06	3.08e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CD—breast cancer	3.1e-06	3.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTGS2—breast cancer	3.09e-06	3.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCL8—breast cancer	3.09e-06	3.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCND1—breast cancer	3.08e-06	3.06e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—JUN—breast cancer	3.07e-06	3.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—HRAS—breast cancer	3.07e-06	3.05e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—TYMS—breast cancer	3.06e-06	3.05e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ALB—breast cancer	3.06e-06	3.04e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SRC—breast cancer	3.05e-06	3.03e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CTNNB1—breast cancer	3.05e-06	3.03e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCL8—breast cancer	3.04e-06	3.02e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PLA2G4A—breast cancer	3.03e-06	3.01e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NCOR1—breast cancer	3.03e-06	3.01e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTM1—breast cancer	3.03e-06	3.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—HRAS—breast cancer	3.02e-06	3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1B—breast cancer	3.02e-06	3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CD—breast cancer	2.99e-06	2.98e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MMP9—breast cancer	2.99e-06	2.97e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—AKT1—breast cancer	2.98e-06	2.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1A—breast cancer	2.98e-06	2.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—breast cancer	2.97e-06	2.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTEN—breast cancer	2.97e-06	2.95e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1B—breast cancer	2.97e-06	2.95e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CA—breast cancer	2.97e-06	2.95e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SERPINE1—breast cancer	2.96e-06	2.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CASP3—breast cancer	2.96e-06	2.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL2—breast cancer	2.95e-06	2.93e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT3—breast cancer	2.94e-06	2.93e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL6—breast cancer	2.94e-06	2.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—AKT1—breast cancer	2.94e-06	2.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—KRAS—breast cancer	2.93e-06	2.91e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—NOS3—breast cancer	2.93e-06	2.91e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CAV1—breast cancer	2.91e-06	2.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CASP3—breast cancer	2.91e-06	2.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK8—breast cancer	2.91e-06	2.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL2—breast cancer	2.9e-06	2.89e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GPX1—breast cancer	2.9e-06	2.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—AKT1—breast cancer	2.9e-06	2.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL6—breast cancer	2.89e-06	2.87e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCND1—breast cancer	2.88e-06	2.86e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP1A1—breast cancer	2.87e-06	2.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—JUN—breast cancer	2.87e-06	2.85e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CB—breast cancer	2.87e-06	2.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CTNNB1—breast cancer	2.85e-06	2.83e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ERCC2—breast cancer	2.85e-06	2.83e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTGS2—breast cancer	2.84e-06	2.82e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCND1—breast cancer	2.83e-06	2.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOS3—breast cancer	2.83e-06	2.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—JUN—breast cancer	2.83e-06	2.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK3—breast cancer	2.81e-06	2.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CTNNB1—breast cancer	2.8e-06	2.79e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MMP9—breast cancer	2.79e-06	2.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1A—breast cancer	2.78e-06	2.77e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTEN—breast cancer	2.78e-06	2.76e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SRC—breast cancer	2.76e-06	2.74e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MMP9—breast cancer	2.75e-06	2.73e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1A—breast cancer	2.74e-06	2.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MYC—breast cancer	2.74e-06	2.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTEN—breast cancer	2.73e-06	2.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TGFB1—breast cancer	2.73e-06	2.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK8—breast cancer	2.72e-06	2.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—AKT1—breast cancer	2.71e-06	2.69e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CB—breast cancer	2.7e-06	2.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTEN—breast cancer	2.7e-06	2.68e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	2.69e-06	2.68e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—breast cancer	2.69e-06	2.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MDM2—breast cancer	2.68e-06	2.67e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTGS2—breast cancer	2.68e-06	2.66e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—MTHFR—breast cancer	2.68e-06	2.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—breast cancer	2.68e-06	2.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK8—breast cancer	2.67e-06	2.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—RAF1—breast cancer	2.67e-06	2.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—AKT1—breast cancer	2.67e-06	2.65e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—RELA—breast cancer	2.66e-06	2.65e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT3—breast cancer	2.66e-06	2.64e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CG—breast cancer	2.65e-06	2.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ERBB2—breast cancer	2.65e-06	2.63e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MTOR—breast cancer	2.61e-06	2.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	2.61e-06	2.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SRC—breast cancer	2.58e-06	2.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK3—breast cancer	2.54e-06	2.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SRC—breast cancer	2.53e-06	2.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KRAS—breast cancer	2.53e-06	2.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCL8—breast cancer	2.51e-06	2.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—breast cancer	2.51e-06	2.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—HRAS—breast cancer	2.49e-06	2.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT3—breast cancer	2.48e-06	2.47e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTEN—breast cancer	2.48e-06	2.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MYC—breast cancer	2.47e-06	2.46e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CAV1—breast cancer	2.47e-06	2.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—breast cancer	2.47e-06	2.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TGFB1—breast cancer	2.46e-06	2.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	2.45e-06	2.43e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT3—breast cancer	2.44e-06	2.43e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	2.42e-06	2.41e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—breast cancer	2.42e-06	2.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CASP3—breast cancer	2.4e-06	2.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL2—breast cancer	2.4e-06	2.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL6—breast cancer	2.39e-06	2.37e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK3—breast cancer	2.37e-06	2.36e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.36e-06	2.34e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CA—breast cancer	2.34e-06	2.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCND1—breast cancer	2.34e-06	2.32e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTEN—breast cancer	2.34e-06	2.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK3—breast cancer	2.34e-06	2.32e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CD—breast cancer	2.33e-06	2.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—JUN—breast cancer	2.33e-06	2.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CA—breast cancer	2.32e-06	2.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	2.31e-06	2.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MYC—breast cancer	2.31e-06	2.29e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ALB—breast cancer	2.3e-06	2.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TGFB1—breast cancer	2.3e-06	2.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KRAS—breast cancer	2.28e-06	2.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MYC—breast cancer	2.27e-06	2.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MMP9—breast cancer	2.27e-06	2.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TGFB1—breast cancer	2.27e-06	2.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	2.26e-06	2.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—breast cancer	2.26e-06	2.24e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTEN—breast cancer	2.26e-06	2.24e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CG—breast cancer	2.25e-06	2.24e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—breast cancer	2.25e-06	2.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—breast cancer	2.22e-06	2.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK8—breast cancer	2.21e-06	2.19e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—NOS3—breast cancer	2.2e-06	2.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—AKT1—breast cancer	2.2e-06	2.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HRAS—breast cancer	2.15e-06	2.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KRAS—breast cancer	2.13e-06	2.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KRAS—breast cancer	2.1e-06	2.09e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	2.1e-06	2.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SRC—breast cancer	2.09e-06	2.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL6—breast cancer	2.06e-06	2.04e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—breast cancer	2.04e-06	2.02e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CB—breast cancer	2.03e-06	2.02e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—breast cancer	2.03e-06	2.02e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT3—breast cancer	2.02e-06	2e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS2—breast cancer	2.02e-06	2e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CD—breast cancer	1.98e-06	1.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	1.96e-06	1.95e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ALB—breast cancer	1.95e-06	1.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HRAS—breast cancer	1.94e-06	1.93e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CA—breast cancer	1.93e-06	1.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK3—breast cancer	1.93e-06	1.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AKT1—breast cancer	1.91e-06	1.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CA—breast cancer	1.9e-06	1.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKT1—breast cancer	1.9e-06	1.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—breast cancer	1.9e-06	1.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MYC—breast cancer	1.87e-06	1.86e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TGFB1—breast cancer	1.87e-06	1.86e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NOS3—breast cancer	1.87e-06	1.86e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—breast cancer	1.87e-06	1.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL6—breast cancer	1.86e-06	1.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—breast cancer	1.83e-06	1.82e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HRAS—breast cancer	1.81e-06	1.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HRAS—breast cancer	1.78e-06	1.77e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTEN—breast cancer	1.76e-06	1.75e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CA—breast cancer	1.75e-06	1.74e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL6—breast cancer	1.73e-06	1.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KRAS—breast cancer	1.73e-06	1.72e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CB—breast cancer	1.72e-06	1.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKT1—breast cancer	1.71e-06	1.7e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS2—breast cancer	1.71e-06	1.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL6—breast cancer	1.71e-06	1.7e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CA—breast cancer	1.65e-06	1.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKT1—breast cancer	1.6e-06	1.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	1.59e-06	1.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKT1—breast cancer	1.58e-06	1.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AKT1—breast cancer	1.55e-06	1.55e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—breast cancer	1.54e-06	1.53e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTEN—breast cancer	1.49e-06	1.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HRAS—breast cancer	1.47e-06	1.46e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AKT1—breast cancer	1.43e-06	1.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6—breast cancer	1.41e-06	1.4e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AKT1—breast cancer	1.35e-06	1.34e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKT1—breast cancer	1.3e-06	1.29e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CA—breast cancer	1.24e-06	1.23e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CA—breast cancer	1.05e-06	1.04e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AKT1—breast cancer	1.01e-06	1.01e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AKT1—breast cancer	8.58e-07	8.53e-06	CbGpPWpGaD
